Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience

Elotuzumab (Elo) is a monoclonal antibody (MoAb) targeting SLAMF7 that has improved overall survival (OS) in combination with the immunomodulatory drugs (IMiDs) lenalidomide (len) or pomalidomide (pom) and dexamethasone (D), in patients with relapsed/refractory multiple myeloma (RRMM) in the ELOQUENT 2 and 3 trials, respectively [ 1 , 2 ]. However, in ELOQUENT 2, patients were not len-refractory or previously treated with daratumumab (Dara) and in ELOQUENT 3, <5% of patients were previously treated with Dara and none were pom-refractory [ 3 , 4 ]. The majority of patients on these trials received 1–3 prior lines of therapy (LOT) and none were triple-class refractory (TCR). The efficacy of Elo+IMiD-based regimens in RRMM patients that are IMiD, Dara-, or TCR and have received >3 prior LOT are poorly characterized. Furthermore, clinical trials evaluating Elo-based regimens in heavily pretreated RRMM patients are lacking given the advent of highly efficacious T-cell mediated therapies such as chimeric-antigen receptor (CAR) T-cell and bispecific antibodies (BsAb) which have revolutionized the treatment of RRMM [ 5 ]. In this retrospective analysis, we aim to evaluate the real-world efficacy and the clinical outcomes of RRMM patients treated with Elo+ImiD+Dex regimens across the 3-site Mayo Clinic Comprehensive Cancer Center (MCCC).